TERN Key Statistics, Chart & Performance
The current stock price of TERN is 36.945 USD. In the past month the price decreased by -14.36%. In the past year, price increased by 675.79%.
TERN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to TERN. When comparing the yearly performance of all stocks, TERN is one of the better performing stocks in the market, outperforming 99.78% of all stocks.
TERN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TERN. While TERN has a great health rating, there are worries on its profitability.
TERN Financial Highlights
Over the last trailing twelve months TERN reported a non-GAAP Earnings per Share(EPS) of -1.03. The EPS increased by 12.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.31% | ||
| ROE | -33.24% | ||
| Debt/Equity | 0 |
TERN Forecast & Estimates
17 analysts have analysed TERN and the average price target is 54.63 USD. This implies a price increase of 47.86% is expected in the next year compared to the current price of 36.945.
TERN Ownership
About TERN
Company Profile
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The company is headquartered in Foster City, California and currently employs 59 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). The company is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
Company Info
TERNS PHARMACEUTICALS INC
1065 East Hillsdale Blvd., Suite 100, Suite 100
Foster City CALIFORNIA 94404 US
CEO: Senthil Sundaram
Employees: 59
Phone: 16505255535
TERNS PHARMACEUTICALS INC / TERN FAQ
Can you describe the business of TERNS PHARMACEUTICALS INC?
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The company is headquartered in Foster City, California and currently employs 59 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). The company is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
What is the stock price of TERNS PHARMACEUTICALS INC today?
The current stock price of TERN is 36.945 USD. The price increased by 6.78% in the last trading session.
Does TERNS PHARMACEUTICALS INC pay dividends?
TERN does not pay a dividend.
How is the ChartMill rating for TERNS PHARMACEUTICALS INC?
TERN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does TERNS PHARMACEUTICALS INC belong to?
TERNS PHARMACEUTICALS INC (TERN) operates in the Health Care sector and the Pharmaceuticals industry.